


Germana Rihetto, Dunja Urosev, Calem Kenward, Saki Konomura, Michael Lee, Franziska von Bank, Ambrose Wu, Adele Chan, Jodi Wong, Allysha Bissessar, Araba Sagoe-Wagner, Lemlem Degefie, Cindy Tong, Andrea Hernandez Rojas, Linglan Fu, Diego A. Alonzo, Spencer Boisjoli, Janice Tsui, Kevin Yin, Elizabeth Porter, Katina Mak, Vincent Fung, Alex Wu, Devika Sim, Kaylee Wu, Vidhi Khanna, Sam Lawn, Karlton Scheu, Sahar Arbabi-Moghdam, Jamie R. Rich, Stuart D. Barnscher
 Author affiliations: Zymeworks Inc., Vancouver, BC, Canada




The development of optimal ADCs relies on the generation of fit for purpose antibodies coupled with drug linker innovation. Here we showcase how Zymeworks is expanding its antibody-based expertise in addition to validated Azymetric™ technology that enables antibody formatting, by implementing diverse and comprehensive antibody discovery, screening and engineering workflows for the development of best-in-class antibodies for ADCs.


Antibody Discovery



Broad Immunization Strategy Leads to the Discovery of Functionally Superior Ly6E Antibody¹




Discovered Antibodies Against an AML Target Have Wide Epitopic Diversity




Antibody Engineering

Affinity Maturation: AI/ML Antibody Engineering Pipeline Overcomes Suboptimal Cyno to Human Antigen Affinity Gap on SPR




Format Diversification

Multivalent Bispecific ADC: Broadening Patient Population and Tumor Mass Coverage



Antibody Pharmacokinetics Optimization: Germline-Guided Engineering Improves PK-Relevant Developability Metrics



Multivalent bispecific Ab formats maintain strong efficacy and the favorable PK of parental mAbs

